Connect Biopharma call centers on rademikibart COPD data
Connect Biopharma hosted an analyst discussion about rademikibart, focusing on the SEABREEZE trial in acute COPD. A University of Alabama at Birmingham pulmonologist joined to explain COPD biology and how patients respond to treatment.
Connect Biopharma held an analyst call centered on rademikibart and the SEABREEZE study in acute COPD. The session included Surya Bhatt, a University of Alabama at Birmingham pulmonary professor who treats advanced COPD and conducts COPD trials.
Bhatt also directs a UAB center focused on AI-based lung imaging research. The conversation began with asthma-versus-COPD differences, including disease biology, airflow obstruction reversibility, patient presentation, and treatment response.
The discussion may matter most to people living with COPD, their caregivers, and clinicians weighing future treatment options. If rademikibart advances, it could influence how acute COPD is managed and how researchers design further studies. Investors and company watchers may also react to how clearly the trial data and expert commentary address the condition, though the call itself does not establish clinical benefit.